Literature DB >> 27056991

A new era for hemophilia B treatment.

Jason A Taylor1, Rebecca Kruse-Jarres2.   

Abstract

In this issue of Blood, Santagostino et al, in their phase 3 study, demonstrate efficacy and safety of recombinant fusion protein linking coagulation factor IX (FIX) with albumin (rIX-FP) which, along with the other 2 extended half-life FIX products, heralds a new era for the treatment of hemophilia B.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27056991      PMCID： PMC4825410          DOI： 10.1182/blood-2016-02-694869

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  7 in total

Review 1.  Extending the pharmacokinetic half-life of coagulation factors by fusion to recombinant albumin.

Authors:  H J Metzner; S W Pipe; T Weimer; S Schulte
Journal:  Thromb Haemost       Date:  2013-08-29       Impact factor: 5.249

2.  Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial.

Authors:  Peter W Collins; Guy Young; Karin Knobe; Faraizah Abdul Karim; Pantep Angchaisuksiri; Claus Banner; Türkiz Gürsel; Johnny Mahlangu; Tadashi Matsushita; Eveline P Mauser-Bunschoten; Johannes Oldenburg; Christopher E Walsh; Claude Negrier
Journal:  Blood       Date:  2014-09-26       Impact factor: 22.113

3.  Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial.

Authors:  Elena Santagostino; Uri Martinowitz; Toshko Lissitchkov; Brigitte Pan-Petesch; Hideji Hanabusa; Johannes Oldenburg; Lisa Boggio; Claude Negrier; Ingrid Pabinger; Mario von Depka Prondzinski; Carmen Altisent; Giancarlo Castaman; Koji Yamamoto; Maria-Teresa Álvarez-Roman; Christine Voigt; Nicole Blackman; Iris Jacobs
Journal:  Blood       Date:  2016-01-11       Impact factor: 22.113

4.  Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B.

Authors:  Claude Negrier; Karin Knobe; Andreas Tiede; Paul Giangrande; Judi Møss
Journal:  Blood       Date:  2011-05-09       Impact factor: 22.113

5.  Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.

Authors:  Marilyn J Manco-Johnson; Thomas C Abshire; Amy D Shapiro; Brenda Riske; Michele R Hacker; Ray Kilcoyne; J David Ingram; Michael L Manco-Johnson; Sharon Funk; Linda Jacobson; Leonard A Valentino; W Keith Hoots; George R Buchanan; Donna DiMichele; Michael Recht; Deborah Brown; Cindy Leissinger; Shirley Bleak; Alan Cohen; Prasad Mathew; Alison Matsunaga; Desiree Medeiros; Diane Nugent; Gregory A Thomas; Alexis A Thompson; Kevin McRedmond; J Michael Soucie; Harlan Austin; Bruce L Evatt
Journal:  N Engl J Med       Date:  2007-08-09       Impact factor: 91.245

6.  Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.

Authors:  Jerry S Powell; K John Pasi; Margaret V Ragni; Margareth C Ozelo; Leonard A Valentino; Johnny N Mahlangu; Neil C Josephson; David Perry; Marilyn J Manco-Johnson; Shashikant Apte; Ross I Baker; Godfrey C Chan; Nicolas Novitzky; Raymond S Wong; Snejana Krassova; Geoffrey Allen; Haiyan Jiang; Alison Innes; Shuanglian Li; Lynda M Cristiano; Jaya Goyal; Jurg M Sommer; Jennifer A Dumont; Karen Nugent; Gloria Vigliani; Aoife Brennan; Alvin Luk; Glenn F Pierce
Journal:  N Engl J Med       Date:  2013-12-04       Impact factor: 91.245

7.  Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients.

Authors:  U Martinowitz; T Lissitchkov; A Lubetsky; G Jotov; T Barazani-Brutman; C Voigt; I Jacobs; T Wuerfel; E Santagostino
Journal:  Haemophilia       Date:  2015-05-20       Impact factor: 4.287
  7 in total
  2 in total

1.  In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates.

Authors:  Tim Preijers; Laura Bukkems; Max van Spengler; Frank Leebeek; Marjon Cnossen; Ron Mathôt
Journal:  Eur J Clin Pharmacol       Date:  2021-02-24       Impact factor: 2.953

2.  Development of Methods for the Selective Measurement of the Single Amino Acid Exchange Variant Coagulation Factor IX Padua.

Authors:  Alfred Weber; Andrea Engelmaier; Dirk Voelkel; Robert Pachlinger; Friedrich Scheiflinger; Paul E Monahan; Hanspeter Rottensteiner
Journal:  Mol Ther Methods Clin Dev       Date:  2018-06-28       Impact factor: 6.698
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.